Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1453 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

AMRI hires new Chemical Development vice president

Lathbury is expected to report to Steven Hagen, vice president of Pharmaceutical Development and Manufacturing. Lathbury will assume leadership for AMRI’s Chemical Development business including operations in Albany,

Thallion Pharma Q3 revenue rises

Thallion Pharma has posted a net loss of $351,394 for the third quarter 2010, or $0.01 loss per diluted share, compared to net loss of $3.03m, or $0.09

Vivalis in research license pact with Kitasato

Vivalis claimed that the EB66 cell line, derived from avian embryonic stem cells, presents characteristics such as genetic stability, immortality and cell growth up to high cell densities

Alkermes Vivitrol gets FDA nod

Alkermes claimed that Vivitrol is a non-narcotic, non-addictive, once-monthly medication approved for the treatment of opioid dependence. The FDA approval of Vivitrol for the prevention of relapse to

Spectrum Pharma names new SVP, acting CFO

Scott will be responsible for all financial aspects of the company and will report directly to the chairman, CEO and president of the company, Rajesh Shrotriya. Most recently

StayinFront partners Morion

The partnership is expected to strengthen StayinFront’s position in Eastern Europe, Russia and CIS and consolidates the physician database and CRM software provision for the region. Morion’s sales